Cellular immunity confers transient protection in experimental buruli ulcer following BCG or mycolactone-negative mycobacterium ulcerans vaccination

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Fraga, Alexandra G ^a,b   Martins, Teresa G ^a,b   Torrado, Egídio ^a,f   Huygen, Kris ^c   Portaels, Françoise ^d   Silva, Manuel T ^e   Castro, António G ^a,b   Pedrosa, Jorge ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e UNIVERSITY OF PORTO   (Portugal)

^f TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 7; MYCOBACTERIUM ULCERANS VACCINE; MYCOBACTERIUM VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; MACROLIDE; MYCOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BURULI ULCER; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; IMMUNIZATION; LYMPH NODE; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN; PROTECTION; SKIN SWELLING; T LYMPHOCYTE; TH1 CELL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY;

MUS; MYCOBACTERIUM ULCERANS;

ANIMALS; BCG VACCINE; BURULI ULCER; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; MACROLIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; NITRIC OXIDE SYNTHASE TYPE II; TH1 CELLS;

EID: 84857837898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033406     Document Type: Article

References (50)

1. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
2. Sizaire V, Nackers F, Comte E, Portaels F, (2006) Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 6: 288-296.
3. Lagarrigue V, Portaels F, Meyers WM, Aguiar J, (2000) [Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin]. Med Trop (Mars) 60: 262-266.
4. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2004) Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 10: 1391-1398.
5. Phanzu DM, Bafende EA, Dunda BK, Imposo DB, Kibadi AK, et al. (2006) Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg 75: 311-314.
6. Portaels F, Zinsou C, Aguiar J, Debacker M, De Biurrun E, et al. (2003) Les atteintes osseuses dan l'Ulcère de Buruli: à propos de 73 cas. BUll Séanc Acad r Sci Outre-Mer 49: 30.
7. Herbinger KH, Brieske D, Nitschke J, Siegmund V, Thompson W, et al. (2009) Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment? Infection 37: 20-25.
8. Rondini S, Mensah-Quainoo E, Junghanss T, Pluschke G, (2006) What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us? J Clin Microbiol 44: 4273-4275.
9. Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, et al. (2006) Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 208: 119-128.
10. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) WHO/CDS/CPE/GBUI/2004.10.
11. Silva MT, Portaels F, Pedrosa J, (2009) Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699-710.
12. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
13. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 79: 421-430.
14. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, et al. (2010) IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 184: 947-955.
15. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73: 6299-6310.
16. Smith PG, Revill WD, Lukwago E, Rykushin YP, (1976) The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 70: 449-457.
17. Uganda Buruli Group (1969) BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1: 111-115.
18. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH, (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Negl Trop Dis 5: e985.
19. Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, et al. (2002) Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 9: 1389-1391.
20. Portaels F, Aguiar J, Debacker M, Guedenon A, Steunou C, et al. (2004) Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 72: 62-65.
21. Tanghe A, Dangy JP, Pluschke G, Huygen K, (2008) Improved Protective Efficacy of a Species-Specific DNA Vaccine Encoding Mycolyl-Transferase Ag85A from Mycobacterium ulcerans by Homologous Protein Boosting. PLoS Negl Trop Dis 2: e199.
22. Tanghe A, Adnet PY, Gartner T, Huygen K, (2007) A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 75: 2642-2644.
23. Fenner F, (1957) Homologous and heterologous immunity in infections of mice with Mycobacterium ulcerans and Mycobacterium balnei. Am Rev Tuberc 76: 76-89.
24. Mve-Obiang A, Lee RE, Portaels F, Small PL, (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774-783.
25. Stinear TP, Hong H, Frigui W, Pryor MJ, Brosch R, et al. (2005) Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol 187: 1668-1676.
26. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T, (2005) A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase. Chembiochem 6: 643-648.
27. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K, (2001) Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 69: 5403-5411.
28. Phillips R, Kuijper S, Benjamin N, Wansbrough-Jones M, Wilks M, et al. (2004) In vitro killing of Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents Chemother 48: 3130-3132.
29. Flynn JL, Chan J, (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
30. Ding AH, Nathan CF, Stuehr DJ, (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
31. Andersen P, Doherty TM, (2005) The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
32. Rodrigues LC, Kerr-Pontes LR, Frietas MV, Barreto ML, (2007) Long lasting BCG protection against leprosy. Vaccine 25: 6842-6844.
33. Cooper AM, (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
34. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
35. Abbas AK, Murphy KM, Sher A, (1996) Functional diversity of helper T lymphocytes. Nature 383: 787-793.
36. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, et al. (2006) Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 177: 1416-1420.
37. Kaufmann SH, (2001) How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 1: 20-30.
38. Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, et al. (2009) Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 198: 69-77.
39. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345-1349.
40. Behr MA, Small PM, (1997) Has BCG attenuated to impotence? Nature 389: 133-134.
41. Einarsdottir T, Huygen K, (2011) Buruli ulcer. Hum Vaccin 7: 1198-1203.
42. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S, (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853-13858.
43. Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, et al. (2001) Immune response to infection with Mycobacterium ulcerans. Infect Immun 69: 1704-1707.
44. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM, (2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70: 5562-5567.
45. Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, et al. (2006) Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 13: 1314-1321.
46. Dobos KM, Spotts EA, Marston BJ, Horsburgh CR Jr, King CH, (2000) Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 6: 158-164.
47. Marsollier L, Deniaux E, Brodin P, Marot A, Wondje CM, et al. (2007) Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med 4: e64.
48. Barral A, Honda E, Caldas A, Costa J, Vinhas V, et al. (2000) Human immune response to sand fly salivary gland antigens: a useful epidemiological marker? Am J Trop Med Hyg 62: 740-745.
49. Burke G, Wikel SK, Spielman A, Telford SR, McKay K, et al. (2005) Hypersensitivity to ticks and Lyme disease risk. Emerg Infect Dis 11: 36-41.
50. Silva MT, Portaels F, Pedrosa J, (2007) Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med 4: e63.